Related references
Note: Only part of the references are listed.Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies
Aurore Palmaro et al.
FUNDAMENTAL & CLINICAL PHARMACOLOGY (2016)
Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus: a systematic literature review
C. E. Henegar et al.
LUPUS (2016)
FINGOLIMOD-ASSOCIATED PML IN A PATIENT WITH PRIOR IMMUNOSUPPRESSION
Tirisham V. Gyang et al.
NEUROLOGY (2016)
Drug-Induced Progressive Multifocal Leukoencephalopathy: Lessons Learned From Contrasting Natalizumab and Rituximab
N. S. Vermeer et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Drug-Induced Progressive Multifocal Leukoencephalopathy: A Comprehensive Analysis of the WHO Adverse Drug Reaction Database
Mauro Melis et al.
CNS DRUGS (2015)
PML in Patients Treated with Dimethyl Fumarate
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Progressive multifocal leukoencephalopathy: new concepts
Marco A. Lima
ARQUIVOS DE NEURO-PSIQUIATRIA (2013)
PML diagnostic criteria Consensus statement from the AAN Neuroinfectious Disease Section
Joseph R. Berger et al.
NEUROLOGY (2013)
Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants
Carlo Piccinni et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2013)
Systemic Lupus Erythematosus, Progressive Multifocal Leukoencephalopathy, and T-CD4+Lymphopenia
Mariana Brandao et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2012)
Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS)
Niklas Schmedt et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps
Fariha Zaheer et al.
THERAPEUTIC ADVANCES IN DRUG SAFETY (2012)
When to publish measures of disproportionality derived from spontaneous reporting databases?
Anthonius de Boer
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Monoclonal Antibodies and Progressive Multifocal Leukoencephalopathy
Daniel L. Keene et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2011)
History and current concepts in the pathogenesis of PML
E. O. MAJOR
CLEVELAND CLINIC JOURNAL OF MEDICINE (2011)
Progressive Multifocal Leukoencephalopathy and Newer Biological Agents
Joseph R. Berger
DRUG SAFETY (2010)
Monoclonal anti body-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project
Kenneth R. Carson et al.
LANCET ONCOLOGY (2009)
Changing incidence of central nervous system diseases in the EuroSIDA cohort
AD Monforte et al.
ANNALS OF NEUROLOGY (2004)
Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database
S Lugardon et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
New insights into progressive multifocal leukoencephalopathy
IJ Koralnik
CURRENT OPINION IN NEUROLOGY (2004)
Share Paper
